Department of Abdominal Oncology, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.
Department of Gastroenterology, West China Hospital, West China Medical School, Sichuan University, Chengdu, 610041, China.
Future Oncol. 2021 Apr;17(12):1553-1569. doi: 10.2217/fon-2020-0829. Epub 2021 Jan 5.
Gastric cancer, a digestive malignancy, is the sixth most frequent cancer and the second leading cause of tumor-related deaths worldwide. The emergence and advancement of immunotherapeutic agents has brought significant survival benefits for patients with gastric cancer and increasingly challenged the conventional therapy pattern involving chemotherapy and target drugs. Furthermore, these breakthroughs have paved the way for immunotherapy, especially with immune checkpoint inhibitors, which act by blocking specific signaling pathways, in particular the CTLA4 pathway and the PD-1/PD-L1 pathway. In this review, we summarize the current trials of immune checkpoint inhibitors in GC and their predictive biomarkers, and discuss their present limitations.
胃癌是一种消化系统恶性肿瘤，是全球第六大常见癌症，也是肿瘤相关死亡的第二大主要原因。免疫治疗药物的出现和发展为胃癌患者带来了显著的生存获益，并日益挑战包括化疗和靶向药物在内的传统治疗模式。此外，这些突破为免疫治疗铺平了道路，特别是免疫检查点抑制剂，通过阻断特定的信号通路，特别是 CTLA4 通路和 PD-1/PD-L1 通路，发挥作用。在这篇综述中，我们总结了免疫检查点抑制剂在 GC 中的当前临床试验及其预测生物标志物，并讨论了它们目前的局限性。
